Comparison of topical nepafenac 0.1% with intravitreal dexamethasone implant for the treatment of Irvine-Gass syndrome

Basit Öğe Kaydı
dc.authoridGüçlü, Hande/0000-0002-3021-0493
dc.authorwosidGüçlü, Hande/AAW-9756-2020
dc.contributor.authorGuclu, Hande
dc.contributor.authorGurlu, Vuslat Pelitli
dc.date.accessioned2024-06-12T11:07:14Z
dc.date.available2024-06-12T11:07:14Z
dc.date.issued2019
dc.departmentTrakya Üniversitesien_US
dc.description.abstractAIM: To compare safety and efficacy of intravitreal dexamethasone (IVD) implant with topical nepafenac (TN) 0.1% in previously untreated Irvine-Gass syndrome (IGS) in clinical practice. METHODS: This was a retrospective study of 62 eyes with IGS after phacoemulsification with posterior chamber intraocular lens (IOL) implantation. None of the patients used treatment before IVD or TN. Best-corrected visual acuity (BCVA) with Early Treatment Diabetic Retinopathy Study chart (ETDRS), slit-lamp, intraocular pressure (IOP) measurement, fundus examination, spectral-domain optical coherence tomography (OCT) and fundus florescein angiography were performed to all subjects at baseline, 1, 3 and 6mo. RESULTS: The mean BCVA of the IVD group was 49.3 +/- 6.8, and the mean BCVA of the TN group was 32.9 +/- 7.3 ETDRS letters in post-treatment month 6. The mean central macular thickness (CRT) of IVD group was 266.6 +/- 53.5 mu m and the mean CRT of TN group was 364.9 +/- 56.3 mu m in post-treatment month 6. Baseline BCVA has correlation with final BCVA in TN group however there was no correlation between baseline BCVA and final BCVA in IVD group. CONCLUSION: IVD is found to be better than TN in controlling pseudophakic macular edema and improving visual acuity. IVD group also has significantly lower CRT however IOP is not significantly different between two groups in post-treatment month 6.en_US
dc.identifier.doi10.18240/ijo.2019.02.12
dc.identifier.endpage267en_US
dc.identifier.issn2222-3959
dc.identifier.issn2227-4898
dc.identifier.issue2en_US
dc.identifier.pmid30809482en_US
dc.identifier.scopus2-s2.0-85061590925en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage258en_US
dc.identifier.urihttps://doi.org/10.18240/ijo.2019.02.12
dc.identifier.urihttps://hdl.handle.net/20.500.14551/21966
dc.identifier.volume12en_US
dc.identifier.wosWOS:000461596100012en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherIjo Pressen_US
dc.relation.ispartofInternational Journal Of Ophthalmologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectIntravitreal Dexamethasone Implanten_US
dc.subjectNepafenacen_US
dc.subjectIrvine-Gass Syndromeen_US
dc.subjectCystoid Macular Edemaen_US
dc.subjectInflammationen_US
dc.subjectCystoid Macular Edemaen_US
dc.subjectTriamcinolone Acetonide Injectionen_US
dc.subjectUnique Nonsteroidal Prodrugen_US
dc.subjectInduced Ocular Inflammationen_US
dc.subjectVascular Caliber Changesen_US
dc.subjectShort-Term Safetyen_US
dc.subjectCataract-Surgeryen_US
dc.subjectPotential Utilityen_US
dc.subjectRisk-Factorsen_US
dc.subjectDiclofenacen_US
dc.titleComparison of topical nepafenac 0.1% with intravitreal dexamethasone implant for the treatment of Irvine-Gass syndromeen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu